Back to Search Start Over

Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved.

Authors :
Wiehe, Kevin
Easterhoff, David
Luo, Kan
Nicely, Nathan I.
Bradley, Todd
Jaeger, Frederick H.
Dennison, S. Moses
Zhang, Ruijun
Lloyd, Krissey E.
Stolarchuk, Christina
Parks, Robert
Sutherland, Laura L.
Scearce, Richard M.
Morris, Lynn
Kaewkungwal, Jaranit
Nitayaphan, Sorachai
Pitisuttithum, Punnee
Rerks-Ngarm, Supachai
Sinangil, Faruk
Phogat, Sanjay
Source :
Immunity (10747613). Dec2014, Vol. 41 Issue 6, p909-918. 10p.
Publication Year :
2014

Abstract

Summary In HIV-1, the ability to mount antibody responses to conserved, neutralizing epitopes is critical for protection. Here we have studied the light chain usage of human and rhesus macaque antibodies targeted to a dominant region of the HIV-1 envelope second variable (V2) region involving lysine (K) 169, the site of immune pressure in the RV144 vaccine efficacy trial. We found that humans and rhesus macaques used orthologous lambda variable gene segments encoding a glutamic acid-aspartic acid (ED) motif for K169 recognition. Structure determination of an unmutated ancestor antibody demonstrated that the V2 binding site was preconfigured for ED motif-mediated recognition prior to maturation. Thus, light chain usage for recognition of the site of immune pressure in the RV144 trial is highly conserved across species. These data indicate that the HIV-1 K169-recognizing ED motif has persisted over the diversification between rhesus macaques and humans, suggesting an evolutionary advantage of this antibody recognition mode. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10747613
Volume :
41
Issue :
6
Database :
Academic Search Index
Journal :
Immunity (10747613)
Publication Type :
Academic Journal
Accession number :
100062098
Full Text :
https://doi.org/10.1016/j.immuni.2014.11.014